A Study of NPT 2042 for Absence Seizures in Genetic Generalized Epilepsy
This study is looking at a new drug called NPT 2042 for people aged 16 to 75 who have genetic generalized epilepsy (GGE) and absence seizures (brief, sudden lapses of consciousness). Researchers want to see if NPT 2042 can reduce how often and how long these seizures happen, compared to a placebo (an inactive substance that looks like the study drug). You would receive either NPT 2042 or placebo, then switch to the other after a break. The main goal is to measure the change in absence seizure frequency over up to 12 weeks. The study is currently recruiting a small number of participants.
- Study design
- This is a single-center, double-blind, crossover study, meaning neither you nor your doctor will know if you are receiving NPT 2042 or placebo. You will receive both NPT 2042 and placebo at different times. The study plans to enroll 12 participants.
- What's involved
- You would take NPT 2042 or placebo by mouth twice a day during two treatment periods, separated by a 14-day washout period. The study will measure the frequency of absence seizures for up to 12 weeks.
- Compensation
- Not stated in the trial record.
- Follow-up
- The primary endpoint measures seizure frequency for up to 12 weeks.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
A Study Evaluating NPT 2042 Versus Placebo in Subjects Aged 16-75 Years With Genetic Generalized Epilepsy (GGE) and Absence Seizures
At a glance
Conditions
Where it's being run
1 sites across 1 statesWho to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Mean and median across subjects of the within subject difference in percent change from treatment period baseline of the frequency of absence seizuresUp to 12 weeks
Mean and median across subjects of the within subject difference in percent change from treatment period baseline of the frequency of absence seizures (defined as 2.5-6 Hz spike-wave bursts lasting greater than 3 seconds) between NPT 2042 and placebo.